JP2022510207A5 - - Google Patents
Info
- Publication number
- JP2022510207A5 JP2022510207A5 JP2021530163A JP2021530163A JP2022510207A5 JP 2022510207 A5 JP2022510207 A5 JP 2022510207A5 JP 2021530163 A JP2021530163 A JP 2021530163A JP 2021530163 A JP2021530163 A JP 2021530163A JP 2022510207 A5 JP2022510207 A5 JP 2022510207A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- derived
- cell
- antigen
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025018442A JP2025072543A (ja) | 2018-12-02 | 2025-02-06 | 増強されたiPSC派生エフェクター細胞を使用した免疫療法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862774278P | 2018-12-02 | 2018-12-02 | |
| US62/774,278 | 2018-12-02 | ||
| PCT/US2019/063024 WO2020117526A1 (en) | 2018-12-02 | 2019-11-25 | IMMUNOTHERAPIES USING ENHANCED iPSC DERIVED EFFECTOR CELLS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025018442A Division JP2025072543A (ja) | 2018-12-02 | 2025-02-06 | 増強されたiPSC派生エフェクター細胞を使用した免疫療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022510207A JP2022510207A (ja) | 2022-01-26 |
| JP2022510207A5 true JP2022510207A5 (cg-RX-API-DMAC7.html) | 2022-12-12 |
Family
ID=70974390
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021530163A Pending JP2022510207A (ja) | 2018-12-02 | 2019-11-25 | 増強されたiPSC派生エフェクター細胞を使用した免疫療法 |
| JP2025018442A Pending JP2025072543A (ja) | 2018-12-02 | 2025-02-06 | 増強されたiPSC派生エフェクター細胞を使用した免疫療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025018442A Pending JP2025072543A (ja) | 2018-12-02 | 2025-02-06 | 増強されたiPSC派生エフェクター細胞を使用した免疫療法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12435123B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3891177A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2022510207A (cg-RX-API-DMAC7.html) |
| KR (1) | KR102943217B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN113166232A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019392265B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021010331A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3121128A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL283607A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021006194A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202105480WA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020117526A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230040337A (ko) * | 2020-06-19 | 2023-03-22 | 페이트 세러퓨틱스, 인코포레이티드 | 면역요법 사용을 위한 iPSC-유래 이펙터 세포 유형들의 조합 |
| CN114525255A (zh) * | 2020-10-30 | 2022-05-24 | 未来智人再生医学研究院(广州)有限公司 | 一种表达il-11的多能干细胞衍生物及其应用 |
| WO2022098914A1 (en) * | 2020-11-04 | 2022-05-12 | Fate Therapeutics, Inc. | Engineered ipsc and persistent immune effector cells |
| US20230405121A1 (en) * | 2020-11-04 | 2023-12-21 | Fate Therapeutics, Inc. | Engineered ipsc and immune effector cells for heterogenous tumor control |
| US11459372B2 (en) | 2020-11-30 | 2022-10-04 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| IL303269A (en) | 2020-12-03 | 2023-07-01 | Century Therapeutics Inc | Genetically engineered cells and uses thereof |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| TW202241935A (zh) | 2020-12-18 | 2022-11-01 | 美商世紀治療股份有限公司 | 具有可調適受體專一性之嵌合抗原受體系統 |
| EP4271798A1 (en) | 2020-12-30 | 2023-11-08 | CRISPR Therapeutics AG | Compositions and methods for differentiating stem cells into nk cells |
| MX2023008809A (es) * | 2021-01-29 | 2023-08-04 | Allogene Therapeutics Inc | ATENUACIÓN O INACTIVACIÓN DE UNO O MÁS DE TAP2, NLRC5, ß2M, TRAC, RFX5, RFXAP Y RFXANK PARA MITIGAR EL RECONOCIMIENTO DE CÉLULAS T DE PRODUCTOS CELULARES ALOGÉNICOS. |
| WO2022179620A1 (zh) * | 2021-02-25 | 2022-09-01 | 克莱格医学有限公司 | Cd94工程化细胞及其组合物 |
| CA3214473A1 (en) * | 2021-04-07 | 2022-10-13 | Century Therapeutics, Inc. | Compositions and methods for generating alpha-beta t cells from induced pluripotent stem cells |
| JP2024522756A (ja) * | 2021-06-18 | 2024-06-21 | オーエヌケイ セラピューティクス リミテッド | ダブルノックアウトナチュラルキラー細胞 |
| US20240307540A1 (en) * | 2021-07-02 | 2024-09-19 | Fate Therapeutics, Inc. | Protected effector cells and use thereof for allogeneic adoptive cell therapies |
| WO2023093763A1 (en) * | 2021-11-24 | 2023-06-01 | Hangzhou Qihan Biotechnology Co., Ltd. | Systems and methods for cell-based immunotherapies cross-reference |
| EP4353741A1 (en) * | 2022-10-14 | 2024-04-17 | ONK Therapeutics Limited | Double knockout natural killer cells |
| WO2024183750A1 (en) * | 2023-03-07 | 2024-09-12 | Qihan Hong Kong Limited | A novel immune cell and use thereof for treating diseases |
| WO2025189046A2 (en) * | 2024-03-06 | 2025-09-12 | The Johns Hopkins University | Pantigen specific cytokine receptor stimulation of immune cell function |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
| GB9710807D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
| GB9725764D0 (en) * | 1997-12-04 | 1998-02-04 | Isis Innovation | HLA-E binding |
| US6140081A (en) | 1998-10-16 | 2000-10-31 | The Scripps Research Institute | Zinc finger binding domains for GNN |
| US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
| US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| JP2002060786A (ja) | 2000-08-23 | 2002-02-26 | Kao Corp | 硬質表面用殺菌防汚剤 |
| US20040224385A1 (en) | 2001-08-20 | 2004-11-11 | Barbas Carlos F | Zinc finger binding domains for cnn |
| US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
| US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| US7972854B2 (en) | 2004-02-05 | 2011-07-05 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| AU2005250408B2 (en) | 2004-05-27 | 2010-09-23 | The Trustees Of The University Of Pennsylvania | Novel artificial antigen presenting cells and uses therefor |
| CN105837690A (zh) | 2006-06-12 | 2016-08-10 | 新兴产品开发西雅图有限公司 | 具有效应功能的单链多价结合蛋白 |
| US7932055B2 (en) | 2006-06-22 | 2011-04-26 | Novo Nordisk A/S | Soluble heterodimeric CD94/NKG2 receptors fusion proteins |
| PT2816112T (pt) | 2009-12-10 | 2018-11-20 | Univ Iowa State Res Found Inc | Modificação do adn modificada pelo efector tal |
| WO2011159726A2 (en) | 2010-06-14 | 2011-12-22 | The Scripps Research Institute | Reprogramming of cells to a new fate |
| MX2014001222A (es) | 2011-07-29 | 2014-09-15 | Univ Pennsylvania | Receptores coestimuladores de cambio. |
| EP2814846B1 (en) | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| SG10201806573TA (en) | 2012-05-25 | 2018-09-27 | Cellectis | Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy |
| IL305629A (en) | 2013-02-15 | 2023-11-01 | Univ California | Chimeric antigen receptor and methods of using it |
| US9932607B2 (en) | 2013-11-15 | 2018-04-03 | The Board Of Trustees Of The Leland Stanford Junior University | Site-specific integration of transgenes into human cells |
| EP3104866A4 (en) | 2014-02-14 | 2017-08-02 | Bellicum Pharmaceuticals, Inc. | Methods for activating t cells using an inducible chimeric polypeptide |
| DK3105335T3 (da) | 2014-02-14 | 2020-01-13 | Univ Texas | Kimære antigenreceptorer og fremgangsmåder til fremstilling heraf |
| CN120536341A (zh) | 2014-03-04 | 2025-08-26 | 菲特治疗公司 | 改良的重编程方法和细胞培养平台 |
| CN113699159A (zh) | 2014-03-28 | 2021-11-26 | 明尼苏达大学评议会 | 涉及经工程改造的cd16的多肽、细胞和方法 |
| AU2015312117A1 (en) | 2014-09-02 | 2017-03-02 | Bellicum Pharmaceuticals, Inc. | Costimulation of chimeric antigen receptors by Myd88 and CD40 polypeptides |
| CN117737124A (zh) | 2015-10-16 | 2024-03-22 | 菲特治疗公司 | 用于诱导和维护基态多能性的平台 |
| CN122146606A (zh) | 2015-11-04 | 2026-06-05 | 菲特治疗公司 | 用于诱导造血细胞分化的方法和组合物 |
| CA3007473A1 (en) | 2015-12-14 | 2017-06-22 | Bellicum Pharmaceuticals, Inc. | Dual controls for therapeutic cell activation or elimination |
| AU2017210031C1 (en) | 2016-01-20 | 2020-11-26 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
| BR112020011017A2 (pt) | 2017-12-22 | 2020-11-17 | Fate Therapeutics, Inc. | células efetoras imunes intensificadas e uso das mesmas |
-
2019
- 2019-11-25 JP JP2021530163A patent/JP2022510207A/ja active Pending
- 2019-11-25 WO PCT/US2019/063024 patent/WO2020117526A1/en not_active Ceased
- 2019-11-25 KR KR1020217019117A patent/KR102943217B1/ko active Active
- 2019-11-25 EP EP19893181.8A patent/EP3891177A4/en active Pending
- 2019-11-25 CA CA3121128A patent/CA3121128A1/en active Pending
- 2019-11-25 AU AU2019392265A patent/AU2019392265B2/en active Active
- 2019-11-25 CN CN201980079481.0A patent/CN113166232A/zh active Pending
- 2019-11-25 SG SG11202105480WA patent/SG11202105480WA/en unknown
- 2019-11-25 BR BR112021010331-7A patent/BR112021010331A2/pt unknown
- 2019-11-25 US US17/297,805 patent/US12435123B2/en active Active
- 2019-11-25 MX MX2021006194A patent/MX2021006194A/es unknown
-
2021
- 2021-06-01 IL IL283607A patent/IL283607A/en unknown
-
2025
- 2025-02-06 JP JP2025018442A patent/JP2025072543A/ja active Pending